News and Press Releases
Principal IRB Becomes Univo IRB With Support From QHP Capital
20 February 2024 -- North Carolina -- Today, Univo IRB was announced as the new company name for Principal IRB. Univo IRB is a next generation institutional review board (IRB) recently acquired...
Category: Clinical Trials
Posted: February 20, 2024
Janssen Submits Type II Extension of Indication Application to the European Medicines Agency Seeking Approval of RYBREVANT (amivantamab), in combination with Lazertinib, for the First-Line Treatment of Patients with EGFR Mutated Non-Small Cell Lung Cancer
The submission is supported by data from the Phase 3 MARIPOSA study, showing statistically significant and clinically meaningful improvement in progression-free survival in patients with EGFR-mutated advanced NSCLC treated with...
Category: Drug Discovery
Posted: February 8, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
First MYC inhibitor to demonstrate safety and anti-tumour activity in a phase 1 first-in-human clinical trial
Developed in-house by VHIO-born spin-off company Peptomyc, OMO-103 is a mini-protein targeting the MYC oncogene which is found deregulated in most, if not all tumor types. Until recently, MYC has...
Category: Drug Discovery
Posted: February 7, 2024
Greenphire Announces Acquisition of Clincierge to Enhance Clinical Trial Support Services
Addition enables sponsors to solve the number one clinical trial participant obstacle – transportation, with a single industry-leading solution 1 February 2024 -- Pennsylvania, US -- Greenphire, a leading innovator in...
Category: Clinical Trials
Posted: February 1, 2024
Almost half of Brits think the Government is doing too little to encourage development of new medicines in the UK
25 January -- London, UK -- Recent YouGov polling commissioned by clinical trials start-up Lindus Health has found that 47% of Brits want the Government to be doing more to...
Category: Pharmaceutical
Posted: January 25, 2024
Phesi releases 2023 analysis of clinical development; breast cancer remains most studied disease area for third year
Annual analysis of data from 95 million patients shows signs of post-pandemic recovery for clinical development industry, but trial cancellation rates at phase 2 remain high 16 January 2024 --...
Category: Clinical Trials
Posted: January 16, 2024
AiCuris Received €15m Milestone Payment from Licensing Partner MSD Following EMA Approval of PREVYMIS for Prevention of CMV Infection in High-Risk Adult Kidney Transplant Recipients
PREVYMIS now approved in the US and Europe for prophylaxis of Cytomegalovirus (CMV) disease in adult kidney transplant recipients at high risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R-]) EMA approval...
Category: Pharmaceutical
Posted: January 9, 2024
Friedrich-Ebert-Str. 475 / Building 302 42117 Wuppertal Germany
Headlands Research Announces Partnership with Sahara Behavioral Health
The collaboration improves access to clinical research and investigational treatments while supporting participant recruitment efforts in Arizona 4 January 2024 -- California, US -- Headlands Research, a leading multinational network...
Category: Clinical Trials
Posted: January 5, 2024
Nanoform Commenced Relative Bioavailability Study of Nanotechnology-Enhanced Enzalutamide
5 January 2024 -- Helsinki, Finland -- Nanoform Finland, the medicine performance enhancing company, today announced it had completed the First Subject First Visit (FSFV) in a trial to evaluate...
Category: Clinical Trials
Posted: January 5, 2024
Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Lazertinib, in combination with RYBREVANT (amivantamab), for the First-Line Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer
The submission is supported by data from the Phase 3 MARIPOSA study, which featured in a Late-Breaking Presidential Symposium session at the 2023 ESMO CongressLazertinib is a highly selective, central...
Category: Clinical Trials
Posted: December 21, 2023
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Lindus Health and Thirty Madison complete enrolment of personalised dermatology care pilot study
14 December 2023 -- London, UK -- Clinical trial company Lindus Health and Thirty Madison, a US-based family of specialised healthcare brands, have today announced the completion of enrolment of...
Category: Clinical Trials
Posted: December 14, 2023
PlaqueTec recruits first ten patients in BIOPATTERN trial
Trial to investigate atherosclerotic cardiovascular diseases receives MHRA approval to continue recruitment towards 300-patient target Unique PlaqueTec Liquid Biopsy System will be used to collect blood samples containing biomolecules localising...
Category: Clinical Trials
Posted: November 29, 2023
Exonate announces successful completion of phase 1b/2a trial in diabetic macular oedema
Lead ophthalmology candidate EXN407 has potential to be the first topical treatment for diabetic retinopathy/diabetic macular oedema EXN407 met all endpoints and displayed encouraging biological activity in diabetic patients with...
Category: Clinical Trials
Posted: November 28, 2023
Commercial study set up times reduced by a third, according to new data
26 October 2023 -- London, England -- New data from the National Institute for Health and Care Research (NIHR) shows that the National Contract Value Review has significantly reduced the...
Category: Clinical Trials
Posted: October 26, 2023
Results from Phase 2 THOR-2 Study Showed Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor Receptor Alterations Treated with Erdafitinib Versus Chemotherapy
Data from Cohort 1 of the phase 2 THOR-2 study showed oral erdafitinib reduced the risk of disease recurrence or death compared with intravesical standard-of-care chemotherapy 21 October 2023 --...
Category: Clinical Trials
Posted: October 23, 2023
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
